Last reviewed 2026-05-28 · How we verify

BUD total dose 800ug

Imperial College London · FDA-approved active Small molecule ✓ Verified May 2026 Quality 1/100

BUD total dose 800ug is a Small molecule drug developed by Imperial College London. It is currently FDA-approved.

BUD (Budesonide) is a small molecule used in the treatment of Chronic Obstructive Lung Disease, as seen in clinical trials studying Symbicort formulations. It is administered in total doses of 400ug/12ug and 800ug/24ug, with the latter also containing Formoterol 24ug.

At a glance

Generic name	BUD total dose 800ug
Sponsor	Imperial College London
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Effect of Symbicort ® on GR in Sputum in COPD (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BUD total dose 800ug CI brief — competitive landscape report
BUD total dose 800ug updates RSS · CI watch RSS
Imperial College London portfolio CI

Frequently asked questions about BUD total dose 800ug

What is BUD total dose 800ug?

BUD total dose 800ug is a Small molecule drug developed by Imperial College London.

Who makes BUD total dose 800ug?

BUD total dose 800ug is developed and marketed by Imperial College London (see full Imperial College London pipeline at /company/imperial-college-london).

What development phase is BUD total dose 800ug in?

BUD total dose 800ug is FDA-approved (marketed).

Manufacturer: Imperial College London — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing